Navigation Links
GeneLink Reports First Quarter Gains
Date:5/11/2010

ORLANDO, Fla., May 11 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, today reported financial results for the fiscal quarter ended March 31, 2010.

Financial Highlights:

  • Continued progress towards profitability: Quarterly operating loss reduced by 14% over Q4 2009
  • Comparable quarter gross profit improvement over Q1 2009 of 37%
  • Q1 Revenues of  $2,221,111, a 12.6% increase over Q1 2009

Gary Beeman, GeneLink's CEO stated, "The first quarter of 2010 continues to reflect the positive impact of the steps initiated in late 2009 to increase our profit margins as GeneLink continued to make progress towards profitability in 2010, with operating losses dropping 14% as compared to the prior quarter.  In addition to continuing our investment in growing and improving the financial performance of our existing GeneWize sales operations, we are focusing on expanding the revenue base at GeneLink in market areas that we previously could not reach."  

Dr. Bernard Kasten, GeneLink's Executive Chairman added, "The first quarter was notable not only for the continued reduction of losses, but more so for the addition of Gary Beeman as CEO.  Gary has already helped GeneLink expand its vision and aspirations in ways which will start to evidence themselves in the coming months in our product offerings, business partnerships, and financial performance."

About GeneLink Biosciences, Inc.:

GeneLink is a 16-year old leading bioscienc
'/>"/>

SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
2. Winner Medical Reports Second Quarter Results for the Fiscal Year 2010
3. China Pharma Holdings, Inc. Reports First Quarter 2010 Financial Results
4. BMP Sunstone Reports First Quarter 2010 Financial Results
5. American Oriental Bioengineering Reports First Quarter 2010 Financial Results
6. OncoGenex Reports First Quarter Financial Results
7. Oncothyreon reports full year and fourth quarter 2009 financial results
8. Oncothyreon reports first quarter 2010 financial results
9. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
10. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
11. Anavex reports animal study results as lead Alzheimers compound approaches phase 1 clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... of Arts and Sciences has received a major ... , Mathew M. Maye, associate professor of chemistry, ... the National Science Foundation (NSF). The award supports ... the results of which may impact gas storage, ... , Maye,s approach is novel, in that he ...
(Date:7/21/2014)... , July 21, 2014  Mike Patterson, CEO ... $1.6 million in Series Seed B funding to ... sensors for the life science, defense, intelligence, and ... Partners led the round and was joined by ... Said Patterson , "This round of funding ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Sleep ... quality are closely correlated with depression. According to ... Health: "About three quarters of depressed patients ... about 40% of young depressed adults and 10% ... The symptoms cause huge distress, have a major ...
(Date:7/20/2014)... (PRWEB) July 20, 2014 NSG ... quartz glass optics, and spectrophotometer calibration ... years, NSG has released many products that have ... product has been their solid-state calibration standards. , ... standards since their release in 2008. NSG ...
Breaking Biology Technology:Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 2How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 3
... Switzerland, May 16 Arpida Ltd.,(SWX: ARPN) today announced ... for review the New Drug Application (NDA) for,intravenous iclaprim ... (cSSSI). Arpida completed the submission of the NDA to,the ... ten month review to,the iclaprim NDA and has established ...
... Million - ... - Gross Profit Up; Net Loss Down -, TUSTIN, ... a vertically integrated specialty pharmaceutical company headquartered,in Tustin, California, with ... subsidiary Jade Pharmaceutical Inc. (JPI),the Company engages in the research, ...
... Principle Reached to Terminate Marketing Agreement with Triax ... on Most Favorable Terms, NAPA, Calif., May 15 ... company engaged in the development,of technologies that target the ... quarter ended March 31, 2008 and an agreement in,principle ...
Cached Biology Technology:Arpida Announces FDA Acceptance of the Iclaprim New Drug Application 2Arpida Announces FDA Acceptance of the Iclaprim New Drug Application 3AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 2AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 3Senetek PLC Reports First Quarter 2008 Financial Results 2Senetek PLC Reports First Quarter 2008 Financial Results 3
(Date:7/21/2014)... cheating in science are among the topics to ... experts in Montreal at the three International Union ... to August 1, 2014. Some 2,000 participants from ... 14th International Congress of Bacteriology and Applied Microbiology, ... Microbiology, and the 16th International Congress of Virology. ...
(Date:7/21/2014)... in areas across Riau province on Sunday, July 20, ... a decline in rainfall. The number of detected ... had been reported one day prior, which had reached ... six regencies and municipalities, most of which were in ... it creates could potentially spread via winds to Malaysia ...
(Date:7/21/2014)... that uses extracts from seeds of Moringa oleifa trees ... 90% to 99%. The hardy trees that are drought ... Asia, and Latin America. , The protocol, which is ... review, is low-cost and efficient, making it especially useful ... who are presently drinking highly turbid and contaminated water. ...
Breaking Biology News(10 mins):Montreal hosts International Union of Microbiology Societies congresses 2
... must address ecological threats, a top international scientific meeting ... the planet,s natural limits in a striking parallel to ... a subprime loan," Dr. Johan Rockstrm of the Stockholm ... risks of both kinds of crises in the future. ...
... a multi-year $1 million sponsored research agreement with ... the maker of Smart Balance buttery spread and ... cholesterol through a patented blend of natural vegetable ... entered into a collaboration and license to develop ...
... 6, 2008, Cambridge, UK ,Discussion of a man,s background, ... and The City episodes in the future, it could ... Risk of developing type 2 diabetes and metabolic ... this background has in turn been influenced by environment and ...
Cached Biology News:Top scientific meeting urges coordinated response to economic and environmental crises 2Brandeis and Smart Balance team up to advance heart-healthy research 2Coping and copulation behavior may help calculate diabetes risk 2